Companies/Medexus Pharmaceuticals Inc.

Company profile

Medexus Pharmaceuticals Inc.

OTC: MEDXF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Bolton, ONReports USD

#350 of 1,394 Healthcare companies by revenue33rd-percentile growth

EA Score

64C

FH 71DQ —GM 48SS 55

v0.1 · 45/100 weight · provisional

↑ operating margin, return on assets · ↓ revenue growth (YoY), 3-yr revenue growth

Methodology →

Revenue TTM

$99.3M

Rev growth YoY (TTM)

-8.3%

Net income (FY)

-$2.4M

Employees

Market cap

$114.6M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$99.3M$99.3M2026

Net income-$2.4M-$2.4M2026

Operating income$5.8M$5.8M2026

Total assets$147.3M$147.3M2026

Liabilities$98.3M$98.3M2026

Equity$49.0M$49.0M2026

Revenue trend

FY2019 – FY2026 · USD

$25.8M

FY19

$58.7M

FY20

$79.7M

FY21

$76.7M

FY22

$108.1M

FY23

$113.1M

FY24

$108.3M

FY25

$99.3M

FY26

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Medexus Pharmaceuticals Inc. booked $99.3M in FY2026 revenue, contracting 8.3% year over year — slower than 67% of Healthcare companies we track, at a -2.4% net margin.

Peers · Healthcare

Harbor Diversified, Inc.——Grown Rogue International Inc.52D Black Diamond Therapeutics, Inc.60C Milestone Pharmaceuticals Inc.——

Key facts

CEOKenneth d'Entremont

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersBolton, ON

ExchangeOTC: MEDXF

Employees82

IPO date2017-11-27

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.